Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07159074 · ClinicalTrials.gov registry record · Phase 2
Repurposing Tilmanocept for Cardiac Sarcoidosis
A Phase 2 study of Cardiac Sarcoidosis, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07159074 is a Phase 2 study of Cardiac Sarcoidosis that is actively recruiting participants, run by Duke University. The registered enrollment target is 15 participants, below the 98-participant average among 3 other Cardiac Sarcoidosis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07159074, a Phase 2 study of Cardiac Sarcoidosis, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if Tc 99m Tilmanocept SPECT/CT imaging can be used to identify cardiac sarcoidosis.
Conditions Studied
Interventions
- DRUG Tc 99m tilmanocept
Study Locations (1)
North Carolina
- Duke University Hospital - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07159074
The ClinicalTrials.gov registry entry for NCT07159074 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 3 other Cardiac Sarcoidosis trials with a reported enrollment target (85% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiac Sarcoidosis appearing as the primary indexed condition, and to 1 intervention - of which Tc 99m tilmanocept is the first listed.
NCT07159074 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT07159074 about?
NCT07159074 is a clinical study titled "Repurposing Tilmanocept for Cardiac Sarcoidosis". The purpose of this study is to see if Tc 99m Tilmanocept SPECT/CT imaging can be used to identify cardiac sarcoidosis.
What is the current status of trial NCT07159074?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2025-09-17. Estimated completion is 2026-12-31.
What conditions does trial NCT07159074 study?
This clinical trial studies the following conditions: Cardiac Sarcoidosis.
What interventions are being tested in trial NCT07159074?
The interventions under investigation include: Tc 99m tilmanocept (DRUG).
Who is sponsoring clinical trial NCT07159074?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07159074 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.